News coverage about Revance Therapeutics (NASDAQ:RVNC) has been trending somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Revance Therapeutics earned a news impact score of 0.15 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.7614537102946 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Revance Therapeutics (NASDAQ:RVNC) traded up 1.57% during midday trading on Friday, reaching $25.80. The company’s stock had a trading volume of 5,567 shares. The stock’s 50-day moving average price is $26.02 and its 200 day moving average price is $23.78. The firm’s market capitalization is $795.13 million. Revance Therapeutics has a 1-year low of $12.35 and a 1-year high of $28.75.
Revance Therapeutics (NASDAQ:RVNC) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($0.93) by $0.03. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. Revance Therapeutics had a negative return on equity of 55.21% and a negative net margin of 32,936.67%. The company’s revenue was up .0% on a year-over-year basis. During the same period last year, the firm earned ($0.88) earnings per share. Equities analysts anticipate that Revance Therapeutics will post ($3.61) EPS for the current fiscal year.
Several analysts recently weighed in on the company. Zacks Investment Research raised Revance Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 price objective on the stock in a research report on Wednesday, August 30th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Revance Therapeutics in a research report on Tuesday, September 26th. BidaskClub raised Revance Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Finally, Piper Jaffray Companies set a $28.00 price objective on Revance Therapeutics and gave the company a “buy” rating in a research report on Wednesday, July 26th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $35.20.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Revance Therapeutics (NASDAQ:RVNC) Stock Price” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/27/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-revance-therapeutics-rvnc-stock-price.html.
In related news, CEO L Daniel Browne sold 22,800 shares of Revance Therapeutics stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $22.76, for a total value of $518,928.00. Following the completion of the transaction, the chief executive officer now directly owns 178,850 shares in the company, valued at $4,070,626. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Lauren P. Silvernail sold 11,164 shares of Revance Therapeutics stock in a transaction dated Thursday, October 12th. The stock was sold at an average price of $26.67, for a total value of $297,743.88. The disclosure for this sale can be found here. Insiders have sold 49,226 shares of company stock valued at $1,196,318 over the last 90 days. Insiders own 18.86% of the company’s stock.
About Revance Therapeutics
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.